SCHEMBL1965133

SCHEMBL1965133

Cc1ccccc1C(=O)Nc1ccc(Cl)c(F)c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DHODH Q02127 1/20 0.63
HPGD P15428 3/20 0.58
MEN1 O00255 2/20 0.58
KMT2A Q03164 2/20 0.58
SMN1; SMN2 Q16637 4/20 0.57
GRM4 Q14833 1/20 0.57
PNLIP P16233 1/20 0.57
ALDH1A1 P00352 2/20 0.56
KCNK3 O14649 1/20 0.56
KCNK9 Q9NPC2 1/20 0.56
FADS1 O60427 1/20 0.56
NPC1 O15118 5/20 0.55
RAB9A P51151 5/20 0.55
MAPT P10636 3/20 0.55
LMNA P02545 1/20 0.55
POLB P06746 1/20 0.55
TP53 P04637 1/20 0.54
THRB P10828 1/20 0.54
AVPR2 P30518 1/20 0.53
OXTR P30559 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29755741 1.00 DHODH (0.63) DHODHHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL19799127 0.87 DHODH (0.68) DHODHHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL4255638 0.87 DHODH (0.73) DHODHHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL27353059 0.83 DHODH (0.63) DHODHHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL18804918 0.82 GRM4 (0.63) DHODHHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL23781713 0.82 HPGD (0.65) DHODHHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL16318340 0.81 FADS1 (0.53) HPGDSMN1; SMN2FADS1NPC1RAB9A
SCHEMBL7334315 0.80 DHODH (0.68) DHODHHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL7331517 0.80 DHODH (0.68) DHODHHPGDMEN1KMT2ASMN1; SMN2
SCHEMBL12259165 0.79 KMT2A (0.72) HPGDMEN1KMT2ASMN1; SMN2ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230037448-A1 FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES NOVIRA THERAPEUTICS, LLC 2023-02-09 US disclosed
CN-114650988-A Fluorinated quinoline and quinoxaline derivatives as inhibitors of dihydroorotate dehydrogenase (DHODH) for the treatment of cancer, autoimmune and inflammatory diseases 詹森生物科技公司 2022-06-21 CN disclosed
WO-2021084500-A1 FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES JANSSEN BIOTECH, INC. (US) 2021-05-06 WO disclosed
EP-2334652-A1 1H-BENZ IMIDAZOLE-5-CARBOXAMIDES AS ANTI-INFLAMMATORY AGENTS Boehringer Ingelheim International GmbH (DE) 2011-06-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230037448-A1 FLUORINATED QUINOLINE AND QUINOXALINE DERIVATIVES AS DIHYDROOROTATE DEHYDROGENASE (DHODH) INHIBITORS FOR THE TREATMENT OF CANCER, AUTOIMMUNE AND INFLAMMATORY DISEASES DHODH, NQO2, DPYD DHODH 1/4885HPGD 119/4885MEN1 1448/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.